

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

March 16, 2021

Approved: April 6, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:**

[REDACTED] (non-voting), [REDACTED]

[REDACTED] (non-voting), [REDACTED]

[REDACTED] non-voting), [REDACTED]

[REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:**

**Consultants Present:**

**Members/Alternates Absent:**

[REDACTED] (Chair) called the meeting to order at 12:34 pm.

**Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 03/02/2021 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed (15-0-0).

**ANNOUNCEMENTS:**

- 1) Report from the Attending Vet
  - a) ACS is working with EH&S to prepare the ABSL3 areas for the AAALAC site visit.
- 2) Report from the IACUC Chair
  - a) Reminded the Committee of next week's AAALAC site visit.
  - b) The Chair reminded the Committee to maintain the utmost levels of professionalism on inspections.

## **OLD BUSINESS**

### **Protocols for Full Committee Review**

**New Protocols:** N/A

**Modifications:** N/A

**Continuations:** N/A

### **Concerns/Issues for Full Committee Discussion**

## **NEW BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

1. **202108692** Novel Mechanisms and Approaches to treat Neonatal Sepsis - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to test the hypothesis that the increased susceptibility to and mortality from sepsis in preterm neonates can be explained by the expansion of MDSCs and the prophylactic administration of adjuvants, will stimulate host protective immunity improving immune cell function. The procedures involved were explained. The reviewers and vets had no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (17-0-0).

2. **202109763** Impact of kava against chronic nicotine promoted lung and pancreatic cancer development in vivo - The reviewer presented this Category E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to evaluate the effect of nicotine, NNK and stress on cancer growth and drug resistance and tests if kava can block such effects. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to table the protocol.

The motion was seconded and passed (16-0-0).

The protocol will return to a future meeting for further review by the Committee.

3. **202110051** Pannexin-1 signaling in abdominal aortic aneurysms - The reviewer presented this Category C, D, & E study using mice and swine. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to define the mechanism by which early stage white blood cell

recruitment is accelerated in males during abdominal aortic aneurysms formation. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

4. **202110069** Assessment of Antineoplastic Agents in Cancer Xenografts in Mice - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee for the use of potential Category E procedures. The goal of this study is to translate immune-stimulatory synthetic materials into routine clinical practice for patients. The procedures involved were explained. The reviewers and vets no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (17-0-1). Since the vote was not unanimous a second motion was made to send the protocol to DMR. The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

5. **202110122** Evaluating anti-inflammatory activity of G1G3 Zipper- The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to characterize the efficacy of engineered galectin constructs to suppress sterile inflammation. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

#### **Modifications:**

6. **IM9\_201809158** Neuromodulation in the olfactory bulb- The reviewer presented this Category C, D, and E study using mice. This study was brought to the Full Committee review for the addition of Category E procedures. The goal of this study is to provide information about how cilia loss, which underlies a large class of human genetic disorders, affects the behavioral changes when neuronal signaling is perturbed by drug use. The procedures involved were explained. The

reviewers had no additional comments. The vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (18-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

7. **IM26\_201810396** Opioid use disorders: UF Pharmacy medications discovery and development - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee review for the addition of Category E experiments. The goal of this study is to identify the pharmacophoric requirements of mitragynine that will lead to templates for the design of novel opioid receptor ligands; this will greatly improve the knowledge of interactions of these structurally novel compounds with opioid receptors and facilitate the development of these ligands as treatments for opioid use disorders. The procedures involved were explained. The reviewers and vets had no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (17-0-0).

8. **IM1\_202009653** Study of Mineralocorticoids - The reviewer presented this Category C and D study using mice. This study was brought to the Full Committee review for the use of non-standard housing (metabolic caging). The goal of this study is to define the function of the aldosterone in the adrenal gland. The procedures involved were explained. The reviewers had no additional comments. The vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations:** N/A

## **OTHER BUSINESS**

- a. DR approval Subsequent to FC Reviews for Protocols from 03/02/2021-03/15/2021
  - i. New: N/A
  - ii. Modifications: IM3\_201910854
  - iii. Continuations: N/A



- b. DR approvals from 03/02/2021-03/15/2021
  - i. New: 202111323, 202110173, 202110174
  - ii. Modifications: IM1\_202009993, IM8\_201809075, IM7\_201910638, IM2\_201909387, IM1\_202110057, IM1\_202011060, IM21\_201810371, IM4\_201810345, IM1\_201908761, IM3\_201810118, IM5\_202009746, IM6\_201910841, IM9\_201910555, IM3\_202011248, IM6\_201810482, IM8\_201810199, IM15\_201910729, IM2\_202011089, IM3\_202011229, IM6\_201907936, IM1\_202011249, IM1\_201910783, IM9\_201808859, IM8\_201910547, IM18\_201810305, IM4\_202009786
  - iii. Continuations: 202008209, 201910604, 201910621, 201910855
- c. Inspection Reports- A motion was made to approve the inspection reports with the changes noted below. The motion was seconded and passed (17-0-0).
  - i. Deficiencies- The Committee reviewed the report. The following corrections were made: page 26 COM 0203 room CB-102-change exposed concrete to chipped paint; page 27 COM 0203 CB-122-change "lid" to "lift";
  - ii. No Deficiencies- The Committee reviewed the report. No changes were requested.
  - iii. Comments- The Committee reviewed the report. No changes were requested.
- d. For Vote: Renewal-Anesthesia and Analgesia Guidelines for Neonatal Rodents- The policy was presented by vet HR. A motion was made to re-approve the policy as submitted. The motion was seconded and passed (17-0-0).
- e. For Vote: Renewal-Unauthorized Animals in UF Housing Animal Research Areas- The policy was presented by the Attending Vet. A motion was made to approve the policy as submitted. The motion was seconded and passed (17-0-0).

#### **Continuing Issues for the Committee:**

- 1. Non-Compliances
  - a. Updates
    - i. Update 2020Oct02/VA update- The update was given by the IACUC Manager. The VA IACUC and corrective actions were presented. The VA has suspended the corresponding protocol and requested grant congruency. The UF corrective actions have not

been completed as of yet, thus the protocol remains suspended. A modification has been submitted for a PI change per the VA corrective actions.

- ii. Update 2021Jan02- The update was given by the IACUC Manager. The lab has completed its initial PAM. An update on the next PAM visits and completed corrective actions will be given.

## 2. Discussion

- a. [REDACTED] PAM findings- The findings were presented by the IACUC Chair. A meeting was held with the PI due to concerns over the high mortality rates in the protocol involved.

**FUTURE MEETINGS:** April 6, 2021  
April 20, 2021

The meeting adjourned at 2:37 pm.

Respectfully submitted,

[REDACTED]

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

May 4, 2021

Approved: May 18, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),  
[REDACTED] (non-voting),  
[REDACTED]  
[REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:** [REDACTED]  
[REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]  
[REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

### **Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 04/20/2021 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed (15-0-0).

### **ANNOUNCEMENTS:**

- 1) Report from the Attending Vet
  - a) An update to the post site visit communication was sent to AAALAC.
- 2) The Chair
  - a) USDA unannounced site visit BEGAN on 05/04/2021. Records were requested and tours of the facilities have begun.
  - b) Full Committee meeting dates for June have been changed to the 8<sup>th</sup> and 22<sup>nd</sup>.

- c) Reminder: IACUC retreat 05/25/2021 at the Straughn Center. Social distancing guidelines will be followed and Zoom will be available.

## **OLD BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

**Modifications:** N/A

**Continuations:** N/A

## **NEW BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

1. **202107398 Mechanisms and treatment for skeletal muscle weakness in heart failure** - The reviewer presented this Category D study using mice. This study was brought to the Full Committee for the use of non-standard humane endpoints (20% weight loss et al.) and possible Category E procedures due to high procedural mortality. The goal of this study is to use surgeries to manipulate specific proteins and understand how they are involved in the breathing difficulties experienced by patients with chronic heart failure. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

2. **202109975\_01 Molecular network reconstruction and reactivation for neural repair** - The reviewer presented this Category C & D study using mice. This study was brought to the Full Committee for requesting the use of a non-pharmaceutical grade drug when pharmaceutical grade is available. The goal of this study is to develop an effective treatment that can regenerate injured/damaged/degenerated spinal cord. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

3. **202110184** Dissecting the mechanisms of tumor-induced tolerance and immune suppression in bladder cancer - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee for the use of Category E procedures.

The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

4. **202110210** Pathological pain behavioral pharmacology - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to establish the pharmacology (cannabinoid receptor mechanisms) responsible for the effects of novel therapeutics. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

5. **202111377** Ursolic acid as a countermeasure to cancer cachexia - The reviewer presented this Category D and E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to investigate ursolic acid as a countermeasure to impede cachexia and improve functional outcomes in patients affected by cancer. The procedures involved were explained. The reviewers had additional comments. The vets had no additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-1-0). Since the first vote was not unanimous, a second motion was made to send the protocol to DMR. The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.



### **Modifications:**

6. **IM26\_201807758** Risk-taking and the nucleus accumbens: neural circuitry and the impact of cocaine - The reviewer presented this Category C, D, & E study using rats. This study was brought to the Full Committee review for deviating from institutional policy on floor space requirements. The goal of this study is to determine the neural circuitry mediating normal risky decision-making and how these circuits become altered by drugs of abuse. The procedures involved were explained. The reviewers and vets had additional comments.. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

7. **IM8\_201908010** Identifying patterns of human polydrug use to guide development of rodent models - The reviewer presented this Category D study using rats. This study was brought to the Full Committee review for requesting the use of non-pharmaceutical oxycodone when pharmaceutical grade is available. The goal of this study is to investigate neuroadaptations in the nucleus accumbens following the self-administration of alcohol and cocaine co-abuse. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

8. **IM2\_201909373** The role of Histone H2B mutations in tumorigenesis - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee review for the addition of Category E procedures. The goal of this study is to generate and characterize a conditional transgenic mouse that carries the mutant H2B gene knocked into the ROSA26 locus. The procedures involved were explained. The reviewers had no further comments. The vets had an additional comment. A motion was made to approve the modification as submitted.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

9. **IM6\_201910762** Targeting NFIB-MAST1 signaling in cisplatin-resistant small cell lung cancer - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee review for the addition of Category E procedures. The goal of this study is to uncover the molecular mechanisms underlying MAST1 and AGGF1 mediated chemo-resistance in lung cancer and identify novel small molecular inhibitors of MAST1 and AGGF1. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-1-0). Since the first vote was not unanimous, a second motion was made to send the protocol to DMR. The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

10. **IM4\_201910854** Effects of cannabis in aging and associated conditions - The reviewer presented this Category C & D study using mice and rats. This study was brought to the Full Committee review for the addition of potential Category E procedures. The goal of this study is to obtain a more firm grasp of the consequences of cannabis use in aging. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

11. **IM1\_202011226** Developing a Novel PROTAC-Based NR4A1 Degradar for Breast Cancer Therapy - The reviewer presented this Category C, D, and E study using mice. This study was brought to the Full Committee review for the addition of Category E procedures. The goal of this study is to focus on the development of new therapeutics mainly targeting on regulatory T cells to enhance anti-cancer immunity to control breast cancer progression, at the same time to suppressive the invasiveness of breast cancer cells. The procedures involved were explained. The reviewers and vets had no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (16-0-0).

**Continuations:** N/A

## **OTHER BUSINESS**

- a. DR approvals from 04/06/2021-05/03/2021
  - i. New: 202110188, 202111329, 202111085, 202111087, 202105745, 202111351, 202110233, 202108884\_01, 202110586
  - ii. Modifications: IM6\_202001838, IM3\_202011089, IM4\_201909599, IM6\_202011147, IM4\_201909539, IM5\_201810345, IM4\_201809010, IM5\_201907843, IM13\_201808822, IM3\_202011244, IM3\_202011121, IM11\_201807707, IM3\_202009909, IM7\_201910777, IM1\_201910737, IM9\_201910792, IM1\_202011278, IM5\_202009685, IM4\_202008644, IM7\_202009746, IM6\_201910541, IM4\_201910617, IM22\_201803042, IM9\_201803393, IM4\_201910570, IM2\_202011153, IM1\_202108890, IM2\_201810239, IM8\_202011140, IM10\_201810280, IM7\_201910841, IM17\_201808863\_01, IM1\_202110284, IM17\_201807438, IM2\_202010059, IM3\_202009941, IM6\_202011101, IM1\_202110069, IM1\_202008562, IM2\_202009986, IM5\_202009751, IM1\_202011295, IM5\_201910909, IM3\_201803505, IM8\_202009739
  - iii. Continuations: 201910713, 201904147
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
  - i. New: 201910958, 202011247, 202111341, 202011301, 202110051, 201910844, 202011188, 202110098, 202111325, 202109763, 202103393
  - ii. Modifications: IM5\_201910891, IM1\_201910770, IM7\_201809059
  - iii. Continuations: N/A
- c. Inspection Reports: Review of the inspection reports was tabled until the next meeting.
- d. For Vote: Policy for Approved Substance/Drug Use in Protocols: Review of the policy was tabled until the next meeting.
- e. For Vote: goIACUC standard library items- mouse euthanasia and corresponding mouse substance administration: Review of the goIACUC standard library items was tabled until the next meeting.

**Continuing Issues for the Committee:**

**1. Non-Compliances**

**a. Reports**

- i. 2021Apr01- The report was presented by the IACUC Manager. Discussion was held by the Committee. A motion was made to accept the events as a non-compliance, reportable to OLAW. The motion was seconded and passed (16-0-0).
- ii. 2021Apr02- The report was presented by the IACUC Manager. Discussion was held by the Committee. A motion was made to accept the events as an adverse event, reportable to OLAW. The motion was seconded and passed (16-0-0).
- iii. 2021Apr03- The report was presented by the IACUC Member [REDACTED]. Discussion was held by the Committee. A suggestion was made to correct the observation times of the vet. The report will be brought back to the next meeting for further discussion by the Committee.
- iv. 2021Apr04- The report was presented by the IACUC Manager. Discussion was held by the Committee. A motion was made to accept the events as a non-compliance, reportable to OLAW. The motion was seconded and passed (15-0-0).

**FUTURE MEETINGS:** May 18, 2021  
June 8, 2021

The meeting adjourned at 5:25 pm.

Respectfully submitted,

[REDACTED]

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

May 18, 2021

Approved: June 8, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),

[REDACTED]  
[REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:** [REDACTED]

[REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]

[REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:32 pm.

### **Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 05/04/2021 meeting.

A motion was made to approve the minutes as submitted.

The motion was seconded and passed (14-0-1) [REDACTED] abstained.

### **ANNOUNCEMENTS:**

- 1) Report from the Attending Vet
  - a) An update on the post site visit communication was received
  - b) The USDA completed their unannounced site visit on 05/12/2021. The final report did not indicate any non-compliant items. The schedule of two labs were requested.



2) The Chair

- a) Reminder: IACUC retreat 05/25/2021 at the Straughn Center. Social distancing guidelines will be followed and Zoom will be available.

**OLD BUSINESS**

**Protocols for Full Committee Review**

**New Protocols:**

**Modifications:** N/A

**Continuations:** N/A

**Concerns/Issues for Full Committee Discussion**

**NEW BUSINESS**

**Protocols for Full Committee Review**

**New Protocols:**

1. **202108822 Physiological Assessment Core for Muscular Dystrophy: Failed Regeneration in the Muscular Dystrophies** - The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to use develop therapies which can promote muscle strength in the presence of muscular dystrophies. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

2. **202110263 A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease** - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for requesting the use of Category E animals. The goal of this study is to test SlpA expressing Lactococcus lactis. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

3. **202111315** Contribution of RAN proteins to HD, SCA3 and other CAG•CTG expansion diseases - The reviewer presented this Category C and D study using mice. This study was brought to the Full Committee for the non-pharmaceutical drugs. The goal of this study is to determine if targeting RAN proteins is a safe and effective therapeutic strategy for Huntington disease and spinocerebellar ataxia type 3. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

4. **202111400** Dealcoholized muscadine wine attenuate arthritis and intestinal inflammation via modulating immune response, gut barrier, and gut microbiota. - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to determine whether concentrated and dealcoholized muscadine wine prevent and alleviate symptoms of rheumatoid arthritis and reduce intestinal inflammation. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to table the protocol.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

5. **202111402** Kratom alkaloids in a mouse sarcoma cancer model - The reviewer presented this Category E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to examine if one kratom alkaloid, mitragynine, possesses utility as an anti-cancer pain therapeutic as well as anti-tumor agent. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

### **Modifications:**

6. **IM4\_201710090** Use Muscadine to Reduce Inflammation and Promote Optimal Gut Health Part 4: the ability of muscadine wine to mitigate inflammatory bowel diseases caused by immune deficiency - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee review for deviating from institutional food and fluid regulation policy. The goal of this study is to test the ability of Muscadine wine to prevent IBD caused by immune deficiency. The procedures involved were explained. The reviewers and vets had additional comments. The vets had no additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

7. **IM8\_201810484** Molecular mechanisms regulating peripheral arterial disease pathobiology in chronic kidney disease - The reviewer presented this Category D & E study using mice. This study was brought to the Full Committee review for the addition of potential Category E animals. The goal of this study is to determine the mechanism underlying the development of skeletal muscle dysfunction in chronic kidney disease. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-1-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and passed. (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

8. **IM6\_201909176** The role of NSD2 methyltransferase in refractory acute lymphocytic leukemia - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee review for requesting the use of nonpharmaceutical grade drug (Bortezimib). The goal of this study is to further our knowledge of lymphoid malignancy progression, as well as help us learn how to best design cancer therapies to target epigenetic dysfunction. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to approve the modification as submitted.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

9. **IM2\_201910950** Treatment Targets for Pulmonary Hypertension Associated with Left Heart Failure - The reviewer presented this Category C and D study using mice. This study was brought to the Full Committee review for requesting the use of Non-pharmaceutical grade drug (Metformin) when a pharmaceutical grade is available. The goal of this study is to evaluate the therapeutic potential of targeting the metabolic pathways in a pulmonary hypertension in left heart failure mouse model. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

10. **IM1\_202108759** Estrogen and Prevention of Hearing Loss - The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee review for the addition of potential Category E procedures. The goal of this study is to provide new basic knowledge of the molecular basis for the cochlear detoxification system and its role in the elimination of chemicals and naturally occurring toxins. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations:** N/A

## **OTHER BUSINESS**

- a. DR approvals from 05/04/2021-05/18/2021
  - i. New: 202111381, 202111345, 202103127, 202110160, 202011311, 202111391
  - ii. Modifications: IM1\_202011224, IM3\_202011094, IM1\_202011247, IM10\_201907966, IM17\_201810535, IM19\_201809165, IM2\_202011189, IM8\_201803399, IM27\_201810396, IM1\_202010038, IM7\_201907968\_01, IM5\_202011031, IM1\_202010056\_01, IM2\_202011015, IM1\_202010124, IM5\_201910617, IM4\_201910948, IM13\_201903567,



IM12\_201807565

- iii. Continuations: 201910687, 202009920, 201910659, 202001838, 201910596
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
  - i. New: 202111370, 202010145, 202111357, 202011180,
  - ii. Modifications: IM2\_202110057, IM9\_201810191, IM9\_201904771, IM1\_202009653, IM26\_201807758, IM4\_201910854
  - iii. Continuations: N/A
- c. Inspection Reports: The Committee reviewed the Inspection reports. The following corrections were made to the Deficiencies report: 05/04/2021- page 4 ARB 0201 room R3-187- correct the spelling of Buprenorphine; 05/18/2021- page 6 BSB 0206 room B2-032- correct the discard date of the sodium chloride. A motion was made to approve the Inspection Reports with the noted corrections. The motion was seconded and passed (15-0-0).
- d. For Vote: Policy for Approved Substance/Drug Use in Protocols- The policy was presented by the IACUC Manager. The Committee discussed the policy. A motion was made to approve the policy as submitted. The motion was seconded and passed (16-0-0).
- e. For Vote: goIACUC standard library items- mouse euthanasia and corresponding mouse substance administration- The library items were presented by the IACUC Manager. The Committee discussed the library items. A motion was made to approve the goIACUC standard library items. The motion was seconded and passed (16-0-0).

#### **Continuing Issues for the Committee:**

##### **1. Non-Compliances**

###### **a. Reports**

- i. 2021Apr03- The report was presented by the IACUC Manager. Discussion was held by the Committee. A motion was made to report the events to OLAW as a non-compliance. The motion was seconded and passed (15-0-0).



**FUTURE MEETINGS:** June 8, 2021  
June 22, 2021  
The meeting adjourned at 3:27 pm.



Final

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

June 1, 2021 Emergency Meeting

Approved: June 22, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of participants.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),  
[REDACTED] (non-voting),  
[REDACTED] on-voting), [REDACTED]

**Guests and Staff Present:** [REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]  
[REDACTED]

**Members/Alternates Absent:** [REDACTED]  
[REDACTED]

[REDACTED] (Chair) called the meeting to order at 2:44 pm.

**Minutes of Prior Meetings:** N/A

**ANNOUNCEMENTS:** N/A

### **OLD BUSINESS**

**Protocols for Full Committee Review:** N/A

### **NEW BUSINESS**

**Protocols for Full Committee Review:** N/A

### **OTHER BUSINESS**

A. Adoption of Veterinary Verification and Consultation (VVC) of Significant Changes Policy- The committee discussed the policy in detail. The policy will be implemented specifically for those protocols requiring euthanasia modifications

due to the present pentobarbital shortage. A motion was made to adopt the policy with the changes discussed. The motion was seconded and passed (13-0-0). Notification will be sent to affected PI's on 06/01/2021. Further implementation will be discussed at a future meeting.

**CONTINUING ISSUES FOR THE COMMITTEE:** N/A

**FUTURE MEETINGS:** June 8, 2021  
June 22, 2021

The meeting adjourned at 3:27 pm.

Respectfully submitted,

A large black rectangular redaction box covering the signature of the meeting minutes.

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

June 8, 2021

Approved: June 22, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),  
[REDACTED] (non-voting),  
[REDACTED] (non-voting),  
[REDACTED] (non-voting),

**Guests and Staff Present:** [REDACTED]

**Consultants Present** [REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

**Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 05/18/2021 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed (11-0-1). [REDACTED] abstained.

**ANNOUNCEMENTS:**

- 1) Report from the Attending Vet
  - a) The surgery schedules for the requested labs were sent to the USDA. A acknowledgement of receipt was received.
  - b) We have not received a definitive date on when AAALAC council will meet to discuss our accreditation. A letter will be sent following, may not be until September

2) The Chair

- a) Target for the first Tuesday in September to resume in-person meetings.

## **OLD BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

- 1) **202111400** Dealcoholized muscadine wine attenuate arthritis and intestinal inflammation via modulating immune response, gut barrier, and gut microbiota. - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to determine whether concentrated and dealcoholized muscadine wine can prevent and alleviate symptoms of rheumatoid arthritis and reduce intestinal inflammation. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (12-1-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and passed (13-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Modifications:** N/A

**Continuations:** N/A

#### **Concerns/Issues for Full Committee Discussion**

## **NEW BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

- 2) **202103016** Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goals of this study are directed toward identifying novel approaches to treat this brain cancer. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.



The motion was seconded and passed (11-0-1). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and passed (11-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 3) **202103495** Extramedullary Hematopoiesis and the Splenic Niche - The reviewer presented this Category D & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to explore bone marrow cells and their structure, placement and movement when they are transplanted. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (10-4-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and but did not pass. (11-2-0).

The protocol will return to a future meeting for further review by the Committee.

- 4) **202107241** Prostate Cancer Progression - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to identify targets for the treatment of advanced Prostate cancer using animal models. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 5) **202107422** Development of exertional heat injury in a conscious mouse model - The reviewer presented this Category D and E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to understand long-term consequences of exertional heat stroke. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 6) **202107438** Hyperbaric oxygen therapy mitigates respiratory neuromuscular pathology after spinal cord injury - The reviewer presented this Category D study using rats. This study was brought to the Full Committee for the use of multiple major survival surgeries, a 20% weight loss endpoint, and non-ACS housing. The goal of this study is to understand how spinal cord neurons and neuronal networks function in relation to breathing, and how we can rehabilitate breathing function in neuromuscular disease using therapeutic methods. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 7) **202108826** Modeling the progression of SOD1-linked motor neuron disease - The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to improve our understanding of how different mutations in SOD1 produce ALS disease that progresses at different rates. The procedures involved were explained. The reviewers had no additional comments. The vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 8) **202108863\_01** A vaccine strategy to overcome treatment induced immunosuppression in glioma - The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to characterize brain tumors and develop novel treatment methods to overcome tumor resistance and growth. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (13-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 9) **202110199** Ionizing radiation induced hematological malignancies- The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to

identify novel mechanisms whereby IR induces HMs and to develop an innovative mechanism-based strategy to prevent their induction. Several strains of transgenic and knockout mice will be exposed to a non-lethal dose of total body irradiation (TBI) to induce senescence. The procedures involved were explained. The reviewers and vets had no additional comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (13-0-0).

**Modifications:**

- 10) **IM8\_201808570** Developing novel tools for targeting mGlu2(3) receptors in methamphetamine addiction. - The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee review for the use of non-pharmaceutical grade drugs. The goal of this study is to design and evaluate mGlu2/3 specific peptides that will be modified for intranasal delivery. The procedures involved were explained. The reviewers and vets had no additional comments. A motion was made to approve the modification as submitted.

The motion was seconded and passed (13-0-0).

- 11) **IM9\_201810195** Chemogenetic modulation of striatal cholinergic interneurons in DYT1 dystonia - The reviewer presented this Category C & D study using mice. This study was brought to the Full Committee review for requesting an exemption to the standard housing policy. The goal of this study is to develop and validate a novel virus-based treatment strategy based on the role of this brain connection in influencing the penetrance and dystonia severity. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made that future submissions either use tunnels in all cages or show substantial specific scientific justification for not using them. All other comments by the reviewers must be addressed to the reviewer's satisfaction for approval.

The motion was seconded and passed (11-2-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and but did not pass. (11-2-0).

The protocol will return to a future meeting for further review by the Committee.

- 12) **IM5\_202005757** Characterization of Meis1 mutant mice and implications in restless legs syndrome and other sleep disorders - The reviewer presented this Category C & D study using mice. This study was brought to the Full Committee review for requesting an exemption to the standard housing policy. The goal of this study is to understand (1) how BTBD9 is involved in RLS, (2) how MEIS1 is involved in RLS, (3) why dopaminergic and opioid treatment works, and (4) what brain regions are important in RLS. The procedures performed were explained. The reviewers and vets had additional comments. A motion was made that future submissions either



use tunnels in all cages or show substantial specific scientific justification for not using them. All other comments by the reviewers must be addressed to the reviewer's satisfaction for approval.

The motion was seconded and passed (10-3-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and but did not pass. (9-3-0).

The protocol will return to a future meeting for further review by the Committee.

- 13) **IM6\_202009761** The Bachmann-Strauss Dystonia & Parkinson's Disease COE Project - The reviewer presented this Category C and E study using mice. This study was brought to the Full Committee review for requesting an exemption to the standard housing policy. The goal of this study is to elucidate the pathophysiology of DYT1, DYT11 dystonias and Amyotrophic lateral sclerosis (ALS) by using genetic mouse models. The procedures performed were explained. The reviewers and vets had additional comments. A motion was made that future submissions either use tunnels in all cages or show substantial specific scientific justification for not using them. All other comments by the reviewers must be addressed to the reviewer's satisfaction for approval.

The motion was seconded and passed (10-3-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and but did not pass. (9-3-0).

The protocol will return to a future meeting for further review by the Committee.

- 14) **IM1\_202011156** The impact of mitochondrial Ca<sup>2+</sup> and ROS in muscle-related conditions - The reviewer presented this Category C, D, and E study using mice. This study was brought to the Full Committee review for the addition of Category E animals. The goal of this study is to test the validity of a new potential therapeutic target to treat people with ALS & Down syndrome. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (11-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations:** N/A

## **OTHER BUSINESS**

- a. DR approvals from 05/04/2021-05/18/2021- review postponed for the next meeting

- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting- review postponed for the next meeting
- c. Inspection Reports- discussion postponed for the next meeting
- d. Updated non-ACS Housing Manual- Proposed updates to the manual were presented by IACUC staff member. The Committee discussed further suggestions. The manual will return to the working group for further editing and return to a future meeting for vote.
- e. Red rat retreat enrichment changes- review postponed for the next meeting
- f. goIACUC rat euthanasia and substance standard library- The library was present by the IACUC Manager. A motion was made to approve the library as submitted. The motion was seconded and passed (12-0-0).
- g. Potential committee member Curriculum Vitae- review postponed for the next meeting

**Continuing Issues for the Committee:**

**1. Non-Compliances**

**a. Reports**


- i. 2021May01- The report was present by the IACUC Manager. A suggestion was made to add "discontinue use of the old irradiator accessories" to the corrective actions. A motion was made to accept the report with the noted suggestion and report the event to OLAW as a non-compliance. The motion was seconded and passed (12-0-0).

**2. Updates- N/A**

**FUTURE MEETINGS:** June 22, 2021

The meeting adjourned at 5:07 pm.

Respectfully submitted,





---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

June 22, 2021

Approved: July 6, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),  
[REDACTED] (non-voting),  
[REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:** [REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]  
[REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

### **Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 06/08/2021 meeting.  
A motion was made to approve the minutes as submitted.  
The motion was seconded and passed (14-0-0).

The committee reviewed and voted on the minutes of the 06/01/2021 emergency meeting.  
A motion was made to approve the minutes as submitted.  
The motion was seconded and passed (12-0-0).

### **ANNOUNCEMENTS:**

- 1) Report from the Attending Vet

- a) The procedures for the surgery schedules that were requested by the USDA occurred with no visit from the VMO. There is only one sheep in-house; otherwise, all sheep work has been completed.
  - b) The official letter has been received from AAALAC international stating that UF has continued, full accreditation. Post site visit communication has been received that no further actions are needed.
  - c) ACS veterinarian [REDACTED] is leaving UF
- 2) The Chair
- a) The Chair gave his official expression of gratitude to everyone for his or her efforts in preparing for the AAALAC visit; special acknowledgement was given to the Attending Vet.

## **OLD BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

- 1) **202103495** Extramedullary Hematopoiesis and the Splenic Niche - The reviewer presented this Category D & E study using mice. This study was returned to the Full Committee for the use of Category E procedures. The goal of this study is to explore bone marrow cells and their structure, placement and movement when they are transplanted. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

#### **Modifications:**

- 2) **IM9\_201810195** Chemogenetic modulation of striatal cholinergic interneurons in DYT1 dystonia - The reviewer presented this Category C & D study using mice. This study was returned to the Full Committee for requesting an exemption to the standard housing policy. The goal of this study is to develop and validate a novel virus-based treatment strategy based on the role of this brain connection in influencing the penetrance and dystonia severity. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-1-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and passed. (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 3) **IM5\_202005757** Characterization of Meis1 mutant mice and implications in restless legs syndrome and other sleep disorders - The reviewer presented this Category C & D study using mice. This study was returned to the Full Committee for requesting an exemption to the standard housing policy. The goal of this study is to understand (1) how BTBD9 is involved in RLS, (2) how MEIS1 is involved in RLS, (3) why dopaminergic and opioid treatment works, and (4) what brain regions are important in RLS. The procedures performed were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-1-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and passed. (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 4) **IM6\_202009761** The Bachmann-Strauss Dystonia & Parkinson's Disease COE Project - The reviewer presented this Category C and E study using mice. This study was returned to the Full Committee for requesting an exemption to the standard housing policy. The goal of this study is to elucidate the pathophysiology of DYT1, DYT11 dystonias and Amyotrophic lateral sclerosis (ALS) by using genetic mouse models. The procedures performed were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-1-0). Since the vote was not unanimous, a second motion was made to return the modification to DMR. The motion was seconded and passed. (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations:** N/A

**Concerns/Issues for Full Committee Discussion**

## **NEW BUSINESS**

### **Protocols for Full Committee Review**

### **New Protocols:**

- 5) **202103306** Animal Care Services rodent breeding protocol - The reviewer presented this Category C & D protocol using mice and rats. This study was brought to the Full Committee to serve as a universal protocol covering procedures used to breed mice and rats in the ACS Rodent Models Breeding Core for use by UF research investigators. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0). ■ recused.

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 6) **202109000** Optimizing Kv7 Channel Openers for Treatment of GWI Pain - The reviewer presented this Category C & E study using rats. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to study treatments for acute and chronic pains associated with other military injuries. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 7) **202110114** Chronic Stress and Anemia Recovery following Major Trauma- The reviewer presented this Category C and E study using rats. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to develop treatment strategies that could eliminate the use of blood transfusions, and will provide great insight as to the explanation of trauma in humans. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 8) **202110195** Chemogenetic modulation of striatal cholinergic interneurons in DYT1 dystonia - The reviewer presented this Category C and D study using mice. This study was brought to the Full Committee for the requesting an exemption from the institutional standard of care policy. The goal of this study is to develop and validate



a novel virus-based treatment strategy based on the role of this brain connection in influencing the penetrance and dystonia severity. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 9) **202111395** Functionalized Enzyme Treatments for Dual-Targeting of Inflammation in Spinal Cord Injury - The reviewer presented this Category C & E study using rats. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to investigate a new anti-inflammatory drug as a therapeutic for spinal cord injury. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 10) **202111397** Methods For Burrow Exclusion and Extraction of Invasive Iguanas - The reviewer presented this Category C & E study using Black Spiny-tailed Iguanas. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to test several methods of iguana exclusion and extraction under controlled conditions to determine if they might be viable options for iguana management. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 11) **202111426** Gammaherpesvirus miRNA suppression of EWSR1 in GC B cell infection and lymphomagenesis - The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to characterize brain tumors and develop novel treatment methods to overcome tumor resistance and growth. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to table the protocol due to unanswered questions by the reviewers

The motion was seconded and passed (15-0-0).



The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Modifications:**

**12) IM6\_201909606 Role of the microbiota in DNA methylation and CRC development.**

- The reviewer presented this Category B, C, & E study using mice. This study was brought to the Full Committee review for the use of non-pharmaceutical grade drugs. The goal of this study is to study the comprehension of dysregulated bacteria/host interaction in the intestine. The procedures involved were explained. The reviewers had no additional comments. The vets had additional comments. A motion was made to approve the modification as submitted.

The motion was seconded and passed (14-0-0).

**13) IM4\_202010059 Kratom alkaloids: in vitro and in vivo pharmacological mechanisms**

- The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee review for the addition of Category E procedures. The goal of this study is to identify effective treatments (substitution therapies) for substance use disorders associated with some of the deadliest substances worldwide: opioids, tobacco, and stimulants. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations: N/A**

**OTHER BUSINESS**

- a. DR approvals from 05/18/2021-06/21/2021
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
- c. Inspection Reports
  - i. 06/08/2021- The Committee reviewed the reports. The following corrections were made to the deficiencies report: 1) page 3 MBI 0059 room L3-166B- clarify the if there was controlled substance at the time of the inspection; 2) page 6 MSB 0445 room MG-017- clarify if the room listed is also on a VA protocol, if so, it must be sent to the VA contact; 3)
  - ii. 06/22/2021- The Committee reviewed the report. The following corrections were made to the deficiencies report: page 2 MSB 0445

room P2-09-clarify if the noted records were from new procedures (Comment per the IACUC Manager- Three records were found where carprofen was given late. They self-corrected this on records after this.)

- iii. A motion was made to approve the inspection reports with the noted corrections and clarifications. The motion was seconded and passed (15-0-0).
- d. For vote: Updated non-ACS manual- The updates were presented by the Chair. A suggestion was made to change “approval” to “consideration” in tier three. A motion was made to adopt tiers one and two of the manual. Negotiations will continue for the outlying agricultural and IFAS units. The motion was seconded and passed (16-0-0).
- e. For vote: Rodent Analgesia Policy- The policy was presented by vet [REDACTED]. The following suggestions were made: 1) delay implementation to allow PIs to be notified, 3) newly submitted protocols and modifications must include the provisions of the new policy, 2) policy will be made effective January 1, 2022 for all protocols. A motion was made to approve the policy with the preceding stipulations. The motion was seconded and passed (16-0-0).
- f. For vote: Proposal to reinstate use of the BMS irradiator for animal irradiation- The proposal was presented by IACUC staff member [REDACTED]. A motion was made to approve the proposal as submitted. The motion was seconded and passed (16-0-0).
- g. For discussion: Red rat retreat enrichment changes- The enrichment changes were presented by the Attending Vet. A suggestion was made to change all references of enrichment to the phrase standard of care. Additional revisions will be brought back to a future meeting for further discussion by the Committee.
- h. For discussion: Potential committee member [REDACTED] and personal philosophy- The Committee discussed the [REDACTED] in detail.

### **Continuing Issues for the Committee:**

#### **1. Non-Compliances**

##### **a. Updates**

- i. For discussion: 2021Apr01 corrective action update- The update was given by IACUC staff member [REDACTED]. The lab completed all corrective actions by last Tuesday.

**FUTURE MEETINGS:** July 6, 2021  
July 20, 2021

The meeting adjourned at 4:50 pm.

Respectfully submitted,



Final

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

October 19, 2021

Approved: November 2, 2021

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),  
[REDACTED]  
[REDACTED]

**Guests and Staff Present:** [REDACTED]  
[REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]  
[REDACTED]

**Members/Alternates Absent:** [REDACTED]  
[REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:36 pm.

### Minutes of Prior Meetings:

The committee reviewed and voted on the minutes of the 10/05/2021 meeting.

The following corrections were made:

Correct the date for [REDACTED] in minutes of prior meetings to 09/21/2021.

Add [REDACTED] to consultants present section.

Change [REDACTED] to the voting members present section as non-voting.

A motion was made to approve the minutes as with the noted changes.

The motion was seconded and passed [(13-0-4) [REDACTED] abstained].

## **ANNOUNCEMENTS:**

- 1) Report from the Attending Vet-
  - a) The Attending Vet reported some animal rights activity against UF. A post by the animal rights group was put on social media to contact President Fuchs to stop animal research at UF.
- 2) From the Chair-
  - a) The Chair reported that new study and triennial submission will be stopped in myIACUC on February 1, 2022.

## **OLD BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

- 1) **202107539** Mucosal Therapy for Autoimmunity - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee the use of Category E animals. [REDACTED]

[REDACTED] The procedures involved were explained. The reviewers had no further comments. The vets had one additional comment. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Modifications:** N/A

**Continuations:** N/A

### **Concerns/Issues for Full Committee Discussion**

## **NEW BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

- 1) **202110396** Opioid use disorders: UF Pharmacy medications discovery and development - The reviewer presented this Category E study using mice and rats. This study was brought to the Full Committee for the use of potential Category E procedures. The goal of this study is to discover medications for opioid use disorder from kratom alkaloids, their metabolites, and mitragynine analogs. The procedures



involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 2) **202110327** Novel adoptive T cell therapy approaches targeting infiltrating tumor cells causing recurrence of high-grade glioma - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to improve the effectiveness of immunotherapies currently tested in clinical trials at the University of Florida for the treatment of Glioblastoma. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to approved the protocol as submitted.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 3) **202110482** Crosstalk between dopamine and glucocorticoids in high levels of nicotine intake and anhedonia in rats- The reviewer presented this Category C & E study using rats. This study was brought to the Full Committee for the use of Category E animals. The goal of this study is to determine the role of dopamine and the stress hormone corticosterone in nicotine self-administration in dependent animals and nicotine withdrawal. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 4) **202109979** The role of iron regulation in acute lung injury and repair - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for the use of Category E animals. The goal of this study is to discover new treatments for humans with acute lung injury. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 5) **202110399** Modulating cancer genetics for immune regulation and breast cancer therapy - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to understand of how obesity-associated inflammation promotes breast/renal cancer progression and identify novel therapeutic to better treat obese patients and improve patient outcomes. The reviewers and vets had additional comments. A motion was made to table the protocol due to unanswered questions.

The motion was seconded and passed (14-0-0). The protocol will be rescheduled to a future meeting for further discussion by the committee.

- 6) **202110194** Gene Immunotherapy in Neuromyelitis optica (NMO) - The reviewer presented this Category D & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to establish a solid gene immunotherapy platform showing that stable expression of a transgene in the liver can restore immune tolerance to neuroproteins in mouse models of Multiple Sclerosis. The reviewers did not have additional comments. The vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 7) **202111551** Notch signaling in allergic airway disease - The reviewer presented this Category C & D study using mice. This study was brought to the Full Committee for the use of potential Category E procedures. The goal of this study is to determine if Jagged 1 expression on dendritic cells alters the balance of T cell secreted factors in an allergic response. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 8) **202111537** Laparoscopic ultrasonography of the liver in 16 healthy dogs: A pilot study - The reviewer presented this Category A & D study using dogs. This study was brought to the Full Committee for the use of privately owned animals for research. The goal of this study is to describe the use and feasibility of laparoscopic ultrasonography of the liver in dogs. The reviewers and vets had additional

comments. A motion was made to require the modifications discussed to secure approval.

The motion and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 9) **202110090** Effect of muscadine grapes and wine on the development of colitis in mice - The reviewer presented this Category C & E study using mice. This study was brought to the Full Committee for the use of Category E procedures. The goal of this study is to test the ability of muscadine wine to prevent IBD caused by immune deficiency in interleukin 10 deficient mice. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Modifications:**

- 10) **IM6\_201910975** Exercise and exercise mimetics to prevent doxorubicin myotoxicity - The reviewer presented this Category D & E study using rats. This study was brought to the Full Committee for the use of Category E animals. The goal of this study is determine the effects of exercise training on the development of DOX- and CP-induced cardiotoxicity. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

- 11) **IM1\_202011171** Mitochondrial permeability transition in aging muscle - The reviewer presented this Category C, D, & E study using mice and rats. This study was brought to the Full Committee for the addition of Category E procedures. The goal of this study is to discover the fundamental mechanisms by which mitochondrial permeability transition causes muscle atrophy. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (15-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations:** N/A

### **OTHER BUSINESS**

- a. DR approvals from 10/05/2021-10/18/2021
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
- c. For vote: Inspection Reports- The following correction was made to the Deficiencies report: Page 12-WANNUT 0478 room 31-change the comment regarding the empty isolators from a minor to significant deficiency. A motion was made to approve the inspection reports with the noted change. The motion was seconded and passed (14-0-0).
- d. Vote for renewal: Guideline for Management of Induced Peritonitis and Ascites- The guideline was presented by vet [REDACTED]. A motion was made to approve the Guideline for Management of Induced Peritonitis and Ascites as submitted. The motion was seconded and passed (13-0-0).
- e. Vote to discontinue Cat. A protocols in myIACUC/goIACUC- The proposal was presented by the IACUC Manager. The option submit Category A protocols do not exist in goIACUC. A checklist for PIs for the need submit documentation with the administration of Category a studies will be included on the website. The overseeing body of Category A protocols will be determined. Approval will discontinue the submission of Category A protocols immediately. The motion was seconded and passed (12-0-0).
- f. Vote to discontinue ACS836 Mouse Breeding online as a required course- The proposal was presented by the IACUC Manager. The course will no longer be mandatory; it will be kept as an optional course. A motion was made to discontinue ACS836 Mouse Breeding online as a required course. The motion was seconded and passed (12-0-0).

**Continuing Issues for the Committee:** N/A

**FUTURE MEETINGS:** November 2, 2021  
November 16, 2021

The meeting adjourned at 4:11 pm.

Respectfully submitted,

[REDACTED]



---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

January 18, 2022

Approved: February 1, 2022

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),

[REDACTED] (non-voting),

[REDACTED] non-voting),

[REDACTED] non-voting),

[REDACTED] (non-voting),

**Guests and Staff Present:** [REDACTED]

**Consultants Present:** [REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:31 pm.

### Minutes of Prior Meetings:

The committee reviewed and voted on the minutes of the 12/21/2021 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed (13-0-0).

### ANNOUNCEMENTS:

- 1) Report from the Attending Vet-
  - a) The Attending Vet informed the Committee that ACS experienced significant staff outages due to COVID-19 infections.



2) From the Chair-

a) Reminders-

- i) Full Committee Member self-evaluations are due to the IACUC Assistant Director by the end of the week.
- ii) ICare webinar via zoom discussing the most common non-compliances that occurred in 2021.
- iii) Interviews for the Attending Vet position will conclude next week. A zoom invite will be sent to any Full Committee member that would like to attend the interview.

**OLD BUSINESS**

**Protocols for Full Committee Review**

**New Protocols:** N/A

**Modifications:** N/A

**Continuations:** N/A

**Concerns/Issues for Full Committee Discussion**

**NEW BUSINESS**

**Protocols for Full Committee Review**

**New Protocols:** N/A

**Modifications:** N/A

**Continuations:** N/A

**OTHER BUSINESS**

- a. DR approvals from 12/21/2021-01/17/2022
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
- c. Presentation/training: ACS Training Core Colony Management- The presentation was given by [REDACTED] and [REDACTED]. The Committee members had a question and answer session after the presentation.
- d. For vote: Training Liaison Program- The program was presented by IACUC staff member [REDACTED]. A motion was made to approve the implementation of the program as submitted. The motion was seconded and passed (17-0-0).

- e. Discussion: Adoption of Animals- The Committee discussed the policy in detail. A suggestion was made to remove the word conspecific from bullet #1. The policy will be brought back to a future meeting for further discussion by the Committee.
- f. Discussion/training: goIACUC- The discussion was led by IACUC staff member [REDACTED]. The official go live date for goIACUC is February 1, 2022. No new studies or triennials will be allowed to be submitted in the myIACUC system after that date. The Committee discussed concerns and gave suggestions regarding the new goIACUC system.
- g. For vote: Marianna-North Florida Research and Education Center- The SOP was presented by the IACUC Assistant Director. A motion was made to approve the SOP as submitted. The motion was seconded and passed (16-0-0).
- h. For vote: IFAS Equine Sciences Center SOP- The SOP was presented by the IACUC Assistant Director. A motion was made to approve the SOP as submitted. The motion was seconded and passed (16-0-0).
- i. For vote: Meat lab- The SOP was presented by the IACUC Assistant Director. A suggestion was made to add objective criteria for assessing "difficult cattle." The SOP will be brought back to a future meeting for further discussion, after the requested changes have been made.
- j. [REDACTED]: information and feedback from the committee- requested Committee members to submit questions to regarding suggestions to be included in the new chapter of the IACUC Handbook on reproducibility.

#### **Continuing Issues for the Committee:**

- a. Non-compliances
  - i. Reports
    - i. For vote: 2021Dec01- The report was presented by IACUC staff member [REDACTED]. A Suggestion was made to remove corrective action #1. A motion was made to approve the report with the noted suggestion as an adverse event reportable to OLAW. The motion was seconded and passed (16-0-0).
    - ii. For vote: 2022Jan01- The report was presented by the IACUC Assistant Director. A Suggestion was made to remove corrective action #1. A motion was made to approve the report as an adverse event reportable to OLAW. The motion was seconded and passed (14-0-0).

ii. Updates

i. Corrective action update: 2021Oct01-

The update was presented by the IACUC Assistant Director. No vote was needed.

**FUTURE MEETINGS:** February 1, 2022  
February 15, 2022

The meeting adjourned at 3:12 pm.

Respectfully submitted,



---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

February 1, 2022

Approved: February 15, 2022

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),  
[REDACTED] (non-voting), [REDACTED] (non-voting),  
[REDACTED]  
[REDACTED] non-voting), [REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:** [REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

### Minutes of Prior Meetings:

The committee reviewed and voted on the minutes of the 01/18/2022 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed [(14-0-1) [REDACTED] abstained].

### ANNOUNCEMENTS:

- 1) Report from the Attending Vet-
  - a) The Attending Vet informed the Committee that ACS staff outages due to COVID-19 infections have lightened.

- 2) From the Chair-
  - a) The Spring SAI sign-up has been sent out electronically. Each Committee member is asked to sign up for at least five dates.
- 3) The Executive Director of ACS informed the Committee that [REDACTED] has been selected to be the new Attending Veterinarian, and will officially start on 02/18/2022. The current Attending Vet will serve as a clinical faculty member until the end of April 2022.

## **OLD BUSINESS**

### **Protocols for Full Committee Review**

**New Protocols:** N/A

**Modifications:** N/A

**Continuations:** N/A

### **Concerns/Issues for Full Committee Discussion**

## **NEW BUSINESS**

### **Protocols for Full Committee Review**

#### **New Protocols:**

**1. 202110488** Using select agent exempt biosafe strains to elucidate ecologic, pathogenic and immunologic mechanisms of disease- The reviewer presented this Category E study using mice. This study was brought to the Full Committee for use of the LD50 test as an assay method and large numbers of animals requested. The goals of this study are to determine the extent of select agent exempt bacterial strain virulence and the relative efficacy of a vaccine for select agent exempt mutants compared to the parental strain. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

#### **Modifications:**

**2. IM3\_202011247** Systemic immuno-inflammatory changes in a novel polytrauma model- The reviewer presented this Category C and E study using rats. This study was brought to the Full Committee for the addition of category E procedures and departure from the Guide (circadian disruption/constant light). The goal of this study is to develop treatment strategies that could



eliminate the use of blood transfusions, and will provide great insight as to the explanation of persistent injury-associated anemia in humans. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**3. IM4\_202107438 Hyperbaric oxygen therapy mitigates respiratory neuromuscular pathology after spinal cord injury-** The reviewer presented this Category D study using rats. This study was brought to the Full Committee for multiple major survival surgeries. The goal of this study is to understand how spinal cord neurons and neuronal networks function in relation to breathing, and how we can rehabilitate breathing function in neuromuscular disease using therapeutic methods. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (16-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**Continuations:** N/A

## **OTHER BUSINESS**

- a. DR approvals from 01/18/2022-01/31/2022
- b. DR approval Subsequent to FC Reviews for Protocols from Last Meeting
- c. Discussion/Presentation: Consent Form Policies for Clinical Studies at the UF Veterinary Hospitals- [REDACTED] and [REDACTED] - The presentation was given and a brief question and answer period was held.
- d. Discussion: Designated Review Assignment
  - i. Transitioning from weekly DR schedule to open assignments based on reviewer specialty/strengths- The discussion was led by the IACUC Assistant Director. A draft of the potential rotation schedule will be brought to a future meeting for further discussion by the Committee.

- e. Discussion: Non-ACS IFAS non-agriculture question
  - i. Do we require a non-ACS manual or an SOP?- The discussion was led by IACUC staff member [REDACTED]. The Committee agreed on using non-ACS manuals.
- f. Discussion: Request to do chicken a project at Non-ACS housing Building 0478 - The discussion was led by the IACUC Assistant Director. A report will be brought back to the Committee for further discussion after contact has been made with the PI to discuss previous issues with the area.
- g. For vote: Meat Processing Center SOP- The SOP was presented by the IACUC Assistant Director. A motion was made to approve the SOP as submitted. The motion was seconded and passed (16-0-0).
- h. For Vote (3 year triennial renewal): Morris Water Maze Guideline- The guideline was presented by vet [REDACTED] and Committee member [REDACTED]. The guideline will return to a future meeting for further discussion by the Committee after revisions have been made by the presenters.
- i. For Vote (3 year triennial renewal): The Use of Physical Restraint of Unanesthetized Research Animals- The guideline was presented by the IACUC Assistant Director. A motion was made to approve the guideline as submitted. The motion was seconded and passed (16-0-0).

**Continuing Issues for the Committee:** N/A

**FUTURE MEETINGS:** February 15, 2022 (Semiannual IO Report)  
March 1, 2022

The meeting adjourned at 2:49 pm.

Respectfully submitted  
[REDACTED]

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

February 15, 2022

Approved: March 1, 2022

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),

[REDACTED] (non-voting),

[REDACTED] (non-voting),

[REDACTED] non-voting),

**Guests and Staff Present:** [REDACTED]

**Consultants Present:** [REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

### Minutes of Prior Meetings:

The committee reviewed and voted on the minutes of the 02/01/2022 meeting.

A motion was made to approve the minutes as submitted.

The motion was seconded and passed [(15-0-1) [REDACTED] abstained].

### ANNOUNCEMENTS:

- 1) Report from the Attending Vet-
  - a) The Attending Vet informed the Committee that ACS staff outages due to COVID-19 infections has lightened.
- 2) From the Chair-
  - a) This is the last meeting of the current Attending Vet.

- b) More inspectors are needed to sign up for a few more spaces to complete the spring semi-annual inspections.
- c) EH&S member [REDACTED] is leaving UF.

**OLD BUSINESS:** N/A

**NEW BUSINESS:** N/A

**OTHER BUSINESS**

- a. DR approvals from 02/01/2022-02/14/2022
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
- c. For vote: Fall 2021 Semiannual IO report- The discussion was lead by the IACUC Chair. A motion was made to approve the Semiannual I/O report as submitted. The motion was seconded and passed (19-0-0). A signature sheet acknowledging receipt of the I/O report will be sent to the Committee members via Docusign. The report will be sent to the I/O for review.
- d. For vote (3 year renewal): Morris Water Maze Guidelines- The discussion was led by the IACUC Assistant Director. A suggestion was made to correct a minor typographical error in the considerations section. A motion was made to approve the Morris Water Maze Guidelines with the suggested correction. The motion was seconded and passed (20-0-0).
- e. For discussion/possible vote: Designated member review process/schedule- Committee members were asked to submit a list of their top three specialties and species to the IACUC Assistant Director. A new assignment rotation will begin once this is received. The rotation will be implemented in a six-month trial, and brought back to the Committee for assessment. A motion was made to adopt the new DMR assignment schedule based on specialty. The motion was seconded and passed (17-1-0).
- f. For discussion: Automatic full committee review
  - i. Current policy: all non-human primate protocols, all Guide departures with the exception of non-pharmaceutical grade use, multiple major survival surgeries, use of Avertin- The Committee discussed the current policy pertaining to departures from the guide that require automatic call to Full Committee review.

- ii. For discussion: Thoughts on recent changes (removal of calling all Cat. E)? Should we add protocols which deviate from our standard humane endpoints? – The discussion was led by vet [REDACTED]. The A motion was made to add protocols which deviate from UF IACUC'S policy for standard humane endpoints, effective immediately. The motion was seconded and passed (17-0-0).
- g. For discussion/possible vote: Guidelines for Maintaining Animal Care Services Procedure Room Space- The Guidelines were presented by the Attending Vet. A motion was made to approve the Guidelines for Maintaining Animal Care Services Procedure Room Space as submitted. The motion was seconded and passed (20-0-0).

**Continuing Issues for the Committee:**

a. Non-compliances

i. Updates:

1. 2021Oct01- The update was presented by the IACUC Assistant Director. Post approval monitoring was performed during a survival surgery procedure on 2/9/2022. Technique concerns were noted by PAM coordinator so ACS veterinary staff observed the next set of surgeries on 2/10/2022. PAM will follow up and observe the next set of surgeries as well.

2. 2021Sept01- The update was presented by the IACUC Assistant Director. The IACUC Assistant Director reminded the Committee that the lab has changed several members and the suspension has been removed. A PAM observation was conducted on 02/15/2022. Two surgeries were done by the lab on 02/14/2022 before the PAM observation. Previous corrective actions required the lab to perform surgeries under PAM observation only for the next twelve months. The Chair requested PAM to do surprise visits to check on the animals that underwent surgery before PAM approval. PAM will increase over the next few months for this lab.

**FUTURE MEETINGS:** March 1, 2022  
March 15, 2022

The meeting adjourned at 2:10 pm.

Respectfully submitted,

[REDACTED]



---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

March 1, 2022

Approved: March 15, 2022

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting),

[REDACTED] (non-voting),

[REDACTED] (non-voting),

[REDACTED] (non-voting),

**Guests and Staff Present:** [REDACTED]

**Consultants Present:** [REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:31 pm.

### **Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 02/15/2022 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed (13-0-0).

### **ANNOUNCEMENTS:**

- 1) Report from the Attending Vet-
  - a) Did not hear any reports or concerns relating to an animal rights event held over the weekend.
  - b) ACS is experiencing staff outages due to COVID-19.
- 2) From the Chair-
  - a) [REDACTED] is retiring from the University of Florida.

**OLD BUSINESS:** N/A

**NEW BUSINESS:**

**New Protocols**

**1. 202210373 Role of iron metabolism in disseminating candidiasis and renal failure-**

The reviewer presented this Category C, D, & E study using mice. This study was brought to the Full Committee for use of Avertin. The goals of this study are to study how iron metabolism affects the dissemination of *C. albicans* and its effect on renal pathology. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**2. 202111546 Safety and Efficacy of Topical Mydriatic Agents in Bearded Dragons (Pogona vitticeps) -**

The reviewer presented this Category C study using bearded dragons. This study was brought to the Full Committee to discuss the use of client-owned animals. The goals of this study are to investigate the efficacy and safety of topically applied neuromuscular blocking agents, as well as a traditional mammalian mydriatic agent, atropine. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

**3. IACUC202100000057 Influenza Co-Infection-** The reviewer presented this Category D & E study using mice. This study was brought to the Full Committee for use of the death as an experimental endpoint. The goal of this study is to design interventions for translational utility. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (17-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

## **Modifications**

**4. IM3\_202011236 Placental-specific therapy for fetal growth restriction-** The reviewer presented this Category C & D study using guinea pigs. This study was brought to the Full Committee for requesting to deviate from USDA cage space requirements during harem breeding. The goals of this study are to determine whether the proposed gene therapy can correct pre-existing Fetal Growth Restriction. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (18-0-0).

The DR will be responsible for assuring that the changes approved by the Committee are incorporated into this protocol.

## **OTHER BUSINESS**

- a. DR approvals from 02/15/2022-02/28/2022
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
- c. For vote: 3 year approval- IFAS Dairy Unit SOP- The Committee discussed the SOP in detail. The suggested edits will be sent to IACUC staff member [REDACTED]. The SOP will be brought back to a future meeting for further discussion.
- d. For vote: 3 year approval- Sheep Physiology Unit SOP- The Committee discussed the SOP in detail. The suggested edits will be sent to IACUC staff member [REDACTED]. The SOP will be brought back to a future meeting for further discussion.
- e. For vote: 3 year approval- Swine Unit SOP- The Committee discussed the SOP in detail. The suggested edits will be sent to IACUC staff member [REDACTED]. The SOP will be brought back to a future meeting for further discussion.
- f. For discussion/vote: Change in ACS ventilated rack change frequency- The discussion was led by the Attending Vet. A motion was made to modify the rack change frequency to 6 months. The motion was seconded and passed (15-0-0).

g. For vote- Review of Standard Procedures-The Standard Procedures were presented by the IACUC Assistant Director. A motion was made to approve the procedures as submitted. The motion was seconded and passed (15-0-0).

i. PROC00001504- Title: Exsanguination cardiac puncture carbon dioxide

Species: Mouse

Procedure Type: Euthanasia

Version Number: 1

ii. PROC00001503- Title: Surgical Scrub povidone-iodine scrub and 70% isopropyl alcohol

Species: Mouse

Procedure Type: Substance Administration

Version Number: 1

iii. PROC00001502- Title: Surgical Scrub 2-4% Chlorhexidine and warmed sterile saline

Species: Mouse

Procedure Type: Substance Administration

Version Number: 1

iv. PROC00001506- Title: Genotyping tail tip <21 days

Species: Mouse

Procedure Type: Tissue/Blood Collection

Version Number: 1

v. PROC00001505- Title: Ophthalmic ointment pre-/peri-operative administration

Species: Mouse

Procedure Type: Substance Administration

Version Number: 1


**FUTURE MEETINGS:** March 15, 2022

April 5, 2022

April 19, 2022

The meeting adjourned at 2:26 pm.

Respectfully submitted,







b) UF Health absorbed Scripps. The IACUC Chair and IACUC Assistant Director to collaborate with the existing administration on a plan to manage the transition. [REDACTED] will be the Institutional Official, [REDACTED] will be the Attending Vet, and the facility will maintain their own vets and animal care staff.

3) IACUC Assistant Director- A notice for the online training IACUC Bootcamp was sent out. Please email the IACUC Assistant Director if attendance is desired.

**OLD BUSINESS:** N/A

**NEW BUSINESS:**

**New Protocols**

**1. 202209933** Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine - The reviewer presented this Category C, D, & E study using mice. This study was brought to requesting an exclusion from the standard housing conditions. The goals of this study are to explore how Tat protein influences dopamine-mediated behaviors in mice, notably the potentiation of cocaine-induced locomotor and reward responses, impairment of learning and memory, and behavioral deficits of mood. The procedures involved were explained. The reviewers had no further comments. The vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-1-0). Since the vote was not unanimous, a second motion was made to return the protocol to the DMR. The motion was seconded but did not pass (14-1-0). A revote on the second motion was made due to everyone that desired to vote not receiving the voting poll. The motion was seconded but did not pass (15-1-0).

The protocol will return to a future meeting for further review by the Committee.

**2. IACUC202100000066** CRM197 to trivalent vaccine - The reviewer presented this Category E study using mice. This study was brought to the Full Committee for use of the death as an experimental endpoint. The goal of this study is to utilize the Spn model, which mimics the natural pathogenesis of Spn, with the purpose of testing a novel trivalent vaccine efficacy against pneumonia infection. The procedures involved were explained. The reviewers and vets had additional comments. A motion was made to require the modifications discussed to secure approval.

The motion was seconded and passed (14-3-0). Since the vote was not unanimous, a second motion was made to return the protocol to the DMR. The motion was seconded but did not pass (14-2-0).

The protocol will return to a future meeting for further review by the Committee.

## **OTHER BUSINESS**

- a. DR approvals from 03/01/2022-03/14/2022
- b. DR approval Subsequent to FC Reviews for Protocols from Last Meeting
- c. Inspection reports- A motion was made to approve the inspection report with the following suggestions:
  - i. Deficiencies- no corrections
  - ii. Deficiencies- COM 0203 room CB-099 (page 13): remove minor deficiency #2 regarding scale calibration; COM 0203 room CB-147 (page 19): PAM will be conducted due to concerns regarding record-keeping for mice- will be brought back to a future meeting to update the Committee on the lab's progress.
  - iii. With Comments- no corrections

The motion was seconded and passed (16-0-0).

- d. Discussion: Reviewer self-identified specialties- please review excel sheet and come prepared to discuss gaps/committee recruitment- The IACUC Chair presented the spreadsheet and requested suggestions for refinement of the categories.
- e. Discussion/training: goIACUC items/updates- The discussion was led by the IACUC Assistant Director. Highlights outlined in each section are as follows
  - i. Review process- Reviewers were asked to click "request clarification" if modifications are needed. Reviewers were also asked to only click approve if completely satisfied with the PIs responses.
  - ii. Triennial blurb- Currently all studies in the goIACUC system are being processed as new protocols, since this initial load does not have a question that delineates triennial studies from new studies. Reviewers are asked to request that PIs put the results of the last 3 years of the study in the basic information section (question 5- summary of research).
  - iii. Reviewer/Anonymous comments- Reviewers were asked to leave their names as a comment to aid the office in answering questions, since reviewer comments are anonymous.

- iv. Literature search- Reviewers were asked to make sure that they review the response for question #1 under Alternatives, Searches, and Duplication. Responses are required for Category D & E procedures, but not Categories B & C.
  - v. Nested substance administration- Reviewers were asked to make sure that they check all of the nested questions under each procedure. Each procedure has a question #4 that may have an attachment that needs to be reviewed.
  - vi. Non-pharmaceutical grade question- Reviewers were reminded that there is no option to identify pharmaceutical grade substances versus non-pharmaceutical grade substances in goIACUC. The PI must specify if the substances used are pharmaceutical grade or not, and if pharmaceutical grade is available.
- f. Discussion: IFAS SOP inconsistencies- The discussion was led by the IACUC Assistant Director. A suggestion was made for IFAS SOP to submit yearly updates. The discussion will return to a future meeting for further discussion by the Committee.
- g. For vote: Standard library items- The Standard library items were presented by the IACUC Assistant Director. A motion was made to approve the Standard library items as submitted. The motion was seconded and passed (16-0-0).
- i. PROC00001636- Title: Ophthalmic ointment pre-/peri-operative administration  
Species: Rat  
Procedure Type: Substance Administration  
Version Number: 1
  - ii. PROC00001638- Title: Surgical Scrub 2-4% Chlorhexidine and warmed sterile saline  
Species: Rat  
Procedure Type: Substance Administration  
Version Number: 1
  - iii. PROC00001640- Title: Surgical Scrub povidone-iodine scrub and 70% isopropyl alcohol  
Species: Rat  
Procedure Type: Substance Administration  
Version Number: 1
  - iv. PROC00001644- Title: Exsanguination cardiac puncture carbon dioxide  
Species: Rat  
Procedure Type: Euthanasia  
Version Number: 1

**FUTURE MEETINGS:** April 5, 2022  
April 19, 2022

The meeting adjourned at 2:41 pm.

Respectfully submitted,



Final

---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

April 5, 2022

Approved: April 19, 2022

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:** [REDACTED] (non-voting), [REDACTED]  
[REDACTED] (non-voting), [REDACTED]  
[REDACTED] non-voting), [REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:** [REDACTED]  
[REDACTED]

**Consultants Present:** [REDACTED]

**Members/Alternates Absent:** [REDACTED]

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

### Minutes of Prior Meetings:

The committee reviewed and voted on the minutes of the 03/15/2022 meeting. The following correction was made: [REDACTED] was not present at the 03/15/2022 meeting. A motion was made to approve the minutes with the noted correction. The motion was seconded and passed (12-0-1). [REDACTED] abstained.

### ANNOUNCEMENTS:

- 1) Report from the Attending Vet-
  - a) The Attending Vet had nothing to report.
- 2) From the Chair-
  - a) The Chair informed the Committee that community member [REDACTED] has resigned from the Committee effective 04/02/2022.
  - b) The Chair informed the Committee of a continuing education opportunity hosted as a collaboration between Johns Hopkins University and the NIH. The workshop



will be held on 06/24/2022 and is regarding how the 3R's interact with reproducibility. Any member that is interested in attending needs to contact the IACUC office.

c) The IO appointed a university-wide committee to address issues concerning the protocol review process. The committee is comprised of half IACUC administration and committee members, and half university research stakeholders.

## **OLD BUSINESS: N/A**

## **NEW BUSINESS:**

### **New Protocols**

**1. 202209933** Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine - The reviewer presented this Category C, D, & E study using mice. This study was brought to requesting an exclusion from the standard housing conditions. The goals of this study are to explore how Tat protein influences dopamine-mediated behaviors in mice, notably the potentiation of cocaine-induced locomotor and reward responses, impairment of learning and memory, and behavioral deficits of mood. The procedures involved were explained. The reviewers had and vets had no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (18-0-0).

**2. IACUC202100000066** CRM197 to trivalent vaccine - The reviewer presented this Category E study using mice. This study was brought to the Full Committee for use of the death as an experimental endpoint. The goal of this study is to utilize the Spn model, which mimics the natural pathogenesis of Spn, with the purpose of testing a novel trivalent vaccine efficacy against pneumonia infection. The procedures involved were explained. The protocol no longer has death as an endpoint and standard a clinical score and humane endpoints will be followed. The reviewers and vets had no further comments. A motion was made to protocol as submitted pending the completion of training requirements noted in goIACUC.

The motion was seconded and passed (18-0-0).

## **OTHER BUSINESS**

- a. DR approvals from 03/15/2022-04/04/2022
- b. DR approval Subsequent to FC Reviews for Protocols from Last Meeting

- c. Inspection reports- A motion was made to approve the inspection report with the following suggestions:

- i. Deficiencies- no corrections

- ii. Deficiencies- COM 0203 room CB-020 (page 1): more information needs to be gathered from the lab regarding significant deficiency; COM 0203 room CB-159A (page 6): remove the comment regarding the modification and the PI will be asked to use pharmaceutical grade saline. If there is scientific justification for non-pharmaceutical grade saline, then a modification will be required; MBI 0059 room L4-131 (page 10): A monthly PAM visit was conducted on 02/15/2022. Discussion of the deficiencies will be brought back to a future committee meeting when the PAM Coordinator is in attendance.

- iii. With Comments- no corrections

The motion was seconded and passed (16-0-0).

- d. For vote: Obtaining Buprenorphine SR via Veterinary Prescription- The requirements were presented by the Attending Vet. A motion was made to approve the requirements as submitted. The vote was seconded and passed (17-0-0).
- e. For vote: Policy on Handling Animals Exposed to Biological Hazards-The policy was presented by the Attending Vet. A motion was made to approve the policy as submitted. The motion was seconded and passed (17-0-0).
  - i. Non-ACS areas will have their own policy created.
- f. For vote: Beef Unit SOP- The Beef SOP was presented by the IACUC Assistant Director. Further discussion of the SOP will be postponed until a future meeting, pending review of the SOP with stakeholders and IACUC administration. A motion was made to set a deadline of forty-five days to bring the SOP back for final IACUC approval. The motion was seconded and approved (15-1-0).
- g. For vote: Investigation of potential noncompliance- The discussion was led by the IACUC Chair. The agenda item will be brought back to a future meeting for further discussion by the Committee.
- h. For vote: Standard library items- The Standard Library Items were presented by the IACUC Assistant Director. A motion was made to approve the Standard library items as submitted. The motion was seconded and passed (17-0-0).

i. PROC00002119

Title: fluid administration\_intraperitoneal\_0.9% saline  
Species: Mouse  
Procedure Type: Substance Administration  
Version Number: 1

ii. PROC00002117

Title: fluid administration\_subcutaneous\_0.9% saline  
Species: Mouse  
Procedure Type: Substance Administration  
Version Number: 1

iii. PROC00002115

Title: fluid administration\_subcutaneous\_0.9% saline  
Species: Rat  
Procedure Type: Substance Administration  
Version Number: 1


iv. PROC00001642

Title: Genotyping tail tip <21 days  
Species: Rat  
Procedure Type: Tissue/Blood Collection  
Version Number: 1

**FUTURE MEETINGS:** April 19, 2022  
May 3, 2022  
May 17, 2022

The meeting adjourned at 2:56 pm.

Respectfully submitted,



---

## INSTITUTIONAL ANIMAL CARE & USE COMMITTEE MINUTES

---

April 19, 2022

Approved: May 3, 2022

A quorum was present and maintained throughout the meeting. The meeting was held via Zoom. During the meeting, some members arrived late, left early, or left the room for various reasons and returned later. Discussions and activities are recorded in the same order as the agenda although the actual order may have varied for convenience of members and investigators.

**Voting Members/Alternates Present:**

[REDACTED] (non-voting), [REDACTED]

[REDACTED] (non-voting), [REDACTED]

[REDACTED] (non-voting), [REDACTED]

**Guests and Staff Present:**

**Consultants Present:**

**Members/Alternates Absent:**

[REDACTED] y

[REDACTED] (Chair) called the meeting to order at 12:30 pm.

**Minutes of Prior Meetings:**

The committee reviewed and voted on the minutes of the 04/05/2022 meeting. A motion was made to approve the minutes as submitted. The motion was seconded and passed (15-0-0).

**ANNOUNCEMENTS:**

- 1) Report from the Attending Vet-
  - a) The Attending Vet reported that a break-in to a lab that uses animals has occurred and a key was stolen. An investigation is currently being conducted by the University Police Department.

- 2) From the Chair-
- a) The Chair informed the Committee that the Chair of the IACUC Improvement Committee would be joining the meeting today to speak to the Full Committee regarding their purpose and objectives.

**OLD BUSINESS:** N/A

**NEW BUSINESS:**

**New Protocols**

**1. IACUC202200000052 Heart Catheterization** - The reviewer presented this Category D study using mice. This study was brought to the Full Committee for requested use of Avertin. The goal of this study is to provide laboratory staff the necessary training to conduct right heart catheterization and left heart catheterization for current and future studies. The procedures involved were explained. The reviewers had and vets had no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (14-0-0).

**2. IACUC202200000083 ROS and diaphragm in HFrEF**- The reviewer presented this Category D study using mice. This study was brought to the Full Committee for multiple major survival surgeries. The goal of this study is to identify the mechanisms which are causative in diaphragm redox imbalance and ROS-mediated contractile dysfunction in CHF. The procedures involved were explained. The reviewers and vets had no further comments. A motion was made to approve the protocol as submitted.

The motion was seconded and passed (15-0-0).

**OTHER BUSINESS**

- a. DR approvals from 04/05/2022-04/18/2022
- b. DR approval Subsequent to FC Reviews for Protocols From Last Meeting
- c. Inspection reports: A motion was made to approve the inspection reports as submitted. The motion was seconded and passed (15-0-0).
- d. Discussion: Follow ups from inspection reports from 4/5/22 meeting: The follow-ups were presented by the Assistant IACUC Director.
  - i. Wang PAM- PAMs are conducted every time the lab conducts a surgery. More PAMs will be scheduled, focusing on other areas. Currently, the PAM coordinator has no concerns.
  - ii. CB-20-DEA- The isolators were noted to still be dirty from the last inspection cycle. The inspectors also observed that there was



moldy food, feces, and moisture in the area. The isolators were not connected to the airflow system and not apparently sealed. The visit will be documented as part of the semi-annual inspection. Formal letters will be written by the IACUC and EH&S regarding the health concerns behind the observed condition to the isolators. Re-inspection will be done after corrective actions are taken and before the room can be used again.

- e. Discussion: Non-ACS-Animal Nutrition-building 0478- Follow up information was presented by the Attending Veterinarian regarding the significant deficiency reported in this room. No further information was requested by the Committee.
- f. For vote: UF IACUC Investigation of Animal Welfare Concerns / Adverse Events / Potential Protocol Non-compliances- The document was presented by the Assistant IACUC Director. The Committee discussed the document in detail. The document will be brought back to a future committee meeting for continued discussion after further revisions are made.
- g. For vote: goIACUC standard procedure PRO00001670- The goIACUC Standard Library Procedure was presented by the Assistant IACUC Director. A motion was made to approve goIACUC Standard Library Procedure PRO00001670 as submitted. The motion was seconded and passed (15-0-0).
- h. Discussion: Horse protocol- The IACUC determined that no protocol is required because this is an observation-only study. The research photo records policy will apply. The PI is requested to provide details regarding client consent. The Chair will follow up with the PI.
- i. Discussion/training: goIACUC- The training was led by the Assistant IACUC Director. Highlights from the training are as follows:
  - i. The Committee's input was requested regarding the newly implemented DMR assignment system
  - ii. The Committee was reminded to check their inboxes daily for protocol assignments
  - iii. An overview of submitting reviews and adding comments to the system was given
  - iv. Review of the animal numbers justification table was done

**FUTURE MEETINGS:** May 3, 2022  
May 17, 2022

The meeting adjourned at 2:45 pm.

Respectfully submitted

